WO2001000185A2 - 1,4-denzothiazepines to treat obesity related disorders - Google Patents
1,4-denzothiazepines to treat obesity related disorders Download PDFInfo
- Publication number
- WO2001000185A2 WO2001000185A2 PCT/EP2000/005541 EP0005541W WO0100185A2 WO 2001000185 A2 WO2001000185 A2 WO 2001000185A2 EP 0005541 W EP0005541 W EP 0005541W WO 0100185 A2 WO0100185 A2 WO 0100185A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrahydro
- benzothiazepine
- alkyl
- carbon atoms
- chloro
- Prior art date
Links
- 0 CC(*)(c1c(*)c(*)c(C)c(*)c11)N(*)C(*)(*)C(*)(*)S1O Chemical compound CC(*)(c1c(*)c(*)c(C)c(*)c11)N(*)C(*)(*)C(*)(*)S1O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of 2,3,4,5-tetrahydro-1 ,4- benzothiazepines in the treatment of obesity, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.
- n 0, 1 or 2;
- , and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);
- R ⁇ to R1 1 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof; with the proviso that:
- the present invention provides a method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula I
- n 0, 1 or 2;
- , and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);
- R8 to Ri 1 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.
- related conditions means eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.
- n 0 or 1 ;
- Ri , R2, R ⁇ and R7 are each H;
- R3 and R4 are independently H or methyl; or together represent imino, methylimino, phenylimino, hydroxyimino or methoxyimi ⁇ o;
- R5 is H or methyl, or when R3 and R4 are independently H or methyl, R5 is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl or ethylsulphonyl;
- R8 is H, methyl, fluoro or chloro
- R9, R10 and R11 are each H; or a pharmaceutically acceptable salt thereof.
- Preferred compounds of formula I are selected from:
- More preferred compounds of formula I are selected from:
- Most preferred compounds of formula I are selected from: 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1 ,4-benzothiazepine;
- a particularly preferred compound of formula I is: 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1 ,4-benzothiazepine; its stereoisomers; and pharmaceutically acceptable salts thereof.
- n 0, 1 or 2;
- , and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);
- R8 to R-11 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof; with the proviso that:
- Ri and R2 are independently H or methyl
- R3 and R4 are independently H or methyl; or together represent imino, methylimino, phenylimino, hydroxyimino or methoxyimino;
- R5 is H or methyl, and when R3 and R4 are H or methyl, R5 is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl or ethylsulphonyl;
- R6 and R7 are each H; and one of R8 to Rn is H, fluoro, chloro, bromo, iodo, methyl (optionally substituted with one or more halo), methoxy (optionally substituted by one or more halo),nitro, cyano, carboxy, acetyl, dimethylcarbamoyl or dimethylsulphamoyl; the remainder of Rs to
- R-11 being H; their stereoisomers; and pharmaceutically acceptable salts thereof.
- R3 and R4 are H, or together are methylimino, phenylimino, hydroxyimino or methoxyimino;
- R5 is H or methyl, and when R3 and R4 are H, R5 is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl, or ethylsulphonyl;
- R8 is H, methyl, fluoro or chloro;
- Rg to Ri 1 are all H; their stereoisomers; and pharmaceutically acceptable salts thereof.
- the compounds of the present invention may prepared and formulated into pharmaceutical formulations as described in WO94/11360.
- the compound of formula I may be administered in any of the known pharmaceutical dosage forms.
- the amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 1000 mg preferably 1 to 500 mg per day given in one or more doses.
- Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions.
- the excipients used in the preparation of these compositions are theexcipients known in the pharmacist's art.
- Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods.
- the tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate.
- the tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention.
- Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.
- capsules for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner.
- the contents of the capsule may be formulated using known methods so as to give sustained release of the active compound.
- the tablets and capsules may conveniently each contain 1 to 500 mg of the active compound.
- the tablets and capsules each contain 5, 10, 15, 20, 25, 30, 50, 100 ,250 or ⁇ OOmg.
- dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
- the active compound may be formulated into granules with or without additional excipients.
- the granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion.
- the granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
- the therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.
- Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
- Dosage forms suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
- Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally.
- a suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol.
- the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base.
- the amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
- the therapeutically active compound of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity.
- Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
- the therapeutically active compounds of formula I used in the method of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body.
- Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused.
- the support may be a single body containing all of the compound or a series of several bodies each containing part of the compound to be delivered.
- the amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
- compositions containing a therapeutically effective amount of a compound of Formula I may be used to treat obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia, and stress in mammals particularly humans, and as an aid to smoking cessation in human beings.
- eating disorders such as bulimia, anorexia, snacking and binge eating
- non-insulin dependent diabetes mellitus such as hyperglycaemia, hyperiipidaemia, and stress in mammals particularly humans
- the amount of active compound administered per day is in the range 1 to 1000 mg preferably 5 to 500 mg given in single or divided doses at one or more times during the day.
- the present invention provides the use of a compound of Formula I in the manufacture of a medicament for use in the treatment of obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia, and stress, and as an aid to smoking cessation.
- eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia, and stress, and as an aid to smoking cessation.
- the present invention also provides a method of treating obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia and stress which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
- eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia and stress which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
- the present invention also provides a method of reducing the craving to smoke in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
- the present invention also provides a method of reducing weight gain after smoking cessation in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
- the compounds of the present invention may be useful in the treatment or prevention of metabolic diseases and conditions arising therefrom, for example non exercise activity thermogenesis and increased metabolic rate.
- the compounds of the present invention may be useful in preventing cardiovascular disease, and in reducing platelet adhesiveness, in aiding weight loss after pregnancy and in aiding weight loss after smoking cessation.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001505895A JP2003513008A (ja) | 1999-06-24 | 2000-06-16 | 治療薬 |
MXPA01013420A MXPA01013420A (es) | 1999-06-24 | 2000-06-16 | Agentes terapeuticos. |
CA002376023A CA2376023A1 (en) | 1999-06-24 | 2000-06-16 | Therapeutic agents |
EP00945759A EP1218010A2 (de) | 1999-06-24 | 2000-06-16 | 1,4-benzothiazepine zur behandlung von fettsuchtverwandten krankheiten |
AU59736/00A AU5973600A (en) | 1999-06-24 | 2000-06-16 | Therapeutic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9914745.6 | 1999-06-24 | ||
GBGB9914745.6A GB9914745D0 (en) | 1999-06-24 | 1999-06-24 | Therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001000185A2 true WO2001000185A2 (en) | 2001-01-04 |
WO2001000185A3 WO2001000185A3 (en) | 2002-04-11 |
Family
ID=10855956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005541 WO2001000185A2 (en) | 1999-06-24 | 2000-06-16 | 1,4-denzothiazepines to treat obesity related disorders |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1218010A2 (de) |
JP (1) | JP2003513008A (de) |
AU (1) | AU5973600A (de) |
CA (1) | CA2376023A1 (de) |
GB (1) | GB9914745D0 (de) |
MX (1) | MXPA01013420A (de) |
WO (1) | WO2001000185A2 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247403B2 (en) | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US8815875B2 (en) | 2008-11-12 | 2014-08-26 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
US8853198B2 (en) | 2012-04-18 | 2014-10-07 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361760A (en) * | 1963-03-21 | 1968-01-02 | Squibb & Sons Inc | Benzothiazepines |
GB1181571A (en) * | 1966-03-10 | 1970-02-18 | Squibb & Sons Inc | Novel 1,4-Benzoxazepine and 1,4-Benzothiazepine Derivatives and Processes for the Preparation Thereof |
EP0444924A1 (de) * | 1990-02-28 | 1991-09-04 | Suntory Limited | Kondensierte 7-gliedrige zyklische Verbindungen und diese enthaltende antipsychotische Zubereitung |
WO1993016055A1 (en) * | 1992-02-17 | 1993-08-19 | The Wellcome Foundation Limited | Hypolipidaemic benzothiazepine compounds |
WO1994011360A1 (en) * | 1992-11-09 | 1994-05-26 | The Boots Company Plc | 1,4-benzothiazepines useful as neurological agents |
WO1996005188A1 (en) * | 1994-08-10 | 1996-02-22 | The Wellcome Foundation Limited | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides |
US5610153A (en) * | 1992-12-11 | 1997-03-11 | Ciba-Geigy Corporation | Benzazepinone derivatives |
US5723458A (en) * | 1993-02-15 | 1998-03-03 | Glaxo Wellcome Inc. | Hypolipidaemic compounds |
EP0864582A2 (de) * | 1997-03-14 | 1998-09-16 | Hoechst Aktiengesellschaft | Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide |
US5817652A (en) * | 1993-02-15 | 1998-10-06 | Glaxo Wellcome Inc. | Hypolipidaemic condensed 1,4-thiazepines |
WO1999009991A1 (en) * | 1997-08-22 | 1999-03-04 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3093419B2 (ja) * | 1992-03-30 | 2000-10-03 | 麒麟麦酒株式会社 | 1,4‐ベンゾチアゼピン誘導体 |
-
1999
- 1999-06-24 GB GBGB9914745.6A patent/GB9914745D0/en not_active Ceased
-
2000
- 2000-06-16 CA CA002376023A patent/CA2376023A1/en not_active Abandoned
- 2000-06-16 MX MXPA01013420A patent/MXPA01013420A/es unknown
- 2000-06-16 EP EP00945759A patent/EP1218010A2/de not_active Withdrawn
- 2000-06-16 WO PCT/EP2000/005541 patent/WO2001000185A2/en not_active Application Discontinuation
- 2000-06-16 JP JP2001505895A patent/JP2003513008A/ja not_active Withdrawn
- 2000-06-16 AU AU59736/00A patent/AU5973600A/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361760A (en) * | 1963-03-21 | 1968-01-02 | Squibb & Sons Inc | Benzothiazepines |
GB1181571A (en) * | 1966-03-10 | 1970-02-18 | Squibb & Sons Inc | Novel 1,4-Benzoxazepine and 1,4-Benzothiazepine Derivatives and Processes for the Preparation Thereof |
EP0444924A1 (de) * | 1990-02-28 | 1991-09-04 | Suntory Limited | Kondensierte 7-gliedrige zyklische Verbindungen und diese enthaltende antipsychotische Zubereitung |
WO1993016055A1 (en) * | 1992-02-17 | 1993-08-19 | The Wellcome Foundation Limited | Hypolipidaemic benzothiazepine compounds |
WO1994011360A1 (en) * | 1992-11-09 | 1994-05-26 | The Boots Company Plc | 1,4-benzothiazepines useful as neurological agents |
US5610153A (en) * | 1992-12-11 | 1997-03-11 | Ciba-Geigy Corporation | Benzazepinone derivatives |
US5723458A (en) * | 1993-02-15 | 1998-03-03 | Glaxo Wellcome Inc. | Hypolipidaemic compounds |
US5817652A (en) * | 1993-02-15 | 1998-10-06 | Glaxo Wellcome Inc. | Hypolipidaemic condensed 1,4-thiazepines |
WO1996005188A1 (en) * | 1994-08-10 | 1996-02-22 | The Wellcome Foundation Limited | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides |
EP0864582A2 (de) * | 1997-03-14 | 1998-09-16 | Hoechst Aktiengesellschaft | Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide |
WO1999009991A1 (en) * | 1997-08-22 | 1999-03-04 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives |
Non-Patent Citations (2)
Title |
---|
DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; "Antihyperlipidaemic benzothiazepines" retrieved from DIALOG Database accession no. 1994184809 XP002183519 & EXPERT OPINION ON THERAPEUTIC PATENTS_(_EXPERT OPIN. THER. PAT._), 1994, 4/6 (717-718), United Kingdom * |
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 05 271208 A (KIRIN BREWERY CO LTD), 19 October 1993 (1993-10-19) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US8247403B2 (en) | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
US8815875B2 (en) | 2008-11-12 | 2014-08-26 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
US8853198B2 (en) | 2012-04-18 | 2014-10-07 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
Also Published As
Publication number | Publication date |
---|---|
GB9914745D0 (en) | 1999-08-25 |
MXPA01013420A (es) | 2002-07-22 |
CA2376023A1 (en) | 2001-01-04 |
JP2003513008A (ja) | 2003-04-08 |
EP1218010A2 (de) | 2002-07-03 |
AU5973600A (en) | 2001-01-31 |
WO2001000185A3 (en) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5942549A (en) | Improving glucose tolerance | |
EP0236684B1 (de) | Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit | |
EP0514452B2 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie | |
AU2016205138A1 (en) | ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease | |
JP2007533733A (ja) | 食物摂取管理の方法 | |
ES2199374T3 (es) | Derivados de 1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina para reducir el nivel de acido urico en seres humanos. | |
US6403641B2 (en) | Therapeutic agents | |
JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
WO2001000185A2 (en) | 1,4-denzothiazepines to treat obesity related disorders | |
WO1998027982A1 (fr) | Composition contenant de l'acide ascorbique | |
EP1162965A1 (de) | Methode zur zügelung der mit therapeutischen medikamenten einhergehenden gewichtszunahme | |
HUT50440A (en) | Process for producing pharmaceutical compositions for treating schizophrenia | |
CA2376886A1 (en) | Therapeutic agents | |
WO1995028933A1 (en) | Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis | |
WO1997023477A1 (en) | Dibenzothiepin derivatives and pharmaceutical compositions | |
AU2730800A (en) | Method to aid smoking cessation | |
US20060063813A1 (en) | Organic compounds | |
JP2002514208A (ja) | 痴呆の治療及び予防におけるシクロオキシゲナーゼ−2阻害剤の使用方法 | |
NL8000332A (nl) | Werkwijze voor het bereiden van een geneesmiddel dat een benzoc 1,6 naftyridine bevat. | |
MXPA01007833A (es) | Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria. | |
CZ9901055A3 (cs) | Léčivo a farmaceutická kompozice pro snižování hladiny kyseliny močové |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase in: |
Ref document number: 2376023 Country of ref document: CA Ref country code: CA Ref document number: 2376023 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/013420 Country of ref document: MX |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2001 505895 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000945759 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10019110 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945759 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000945759 Country of ref document: EP |